Comparative Pharmacology
Head-to-head clinical analysis: DURADYNE DHC versus ROXILOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURADYNE DHC versus ROXILOX.
DURADYNE DHC vs ROXILOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours.
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Category C
Category C
Opioid Analgesic
Opioid Analgesic